1,519
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis.

          Related collections

          Author and article information

          Journal
          N Engl J Med
          The New England journal of medicine
          Massachusetts Medical Society
          0028-4793
          0028-4793
          November 23 2000
          : 343
          : 21
          Affiliations
          [1 ] Institute for Work and Health, Mount Sinai Hospital, and the University Health Network, Toronto, ON, Canada. claire.bombardier@utoronto.ca
          Article
          10.1056/NEJM200011233432103
          11087881
          c9ae2e9f-5224-423e-bac2-effe3ac60a94
          History

          Comments

          Comment on this article